Forte Biosciences, Inc. (FBRX)
76.94
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
76.94
0.00 (0.00%)
After-Hours: 20:00
Forte Biosciences Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 4.480 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 1.911 |
| June 30, 2019 | 1.005 |
| March 31, 2019 | 0.8181 |
| December 31, 2018 | 0.4506 |
| September 30, 2018 | 0.5466 |
| June 30, 2018 | 0.5622 |
| March 31, 2018 | 0.1537 |
| December 31, 2017 | 0.1523 |
| September 30, 2017 | 0.1557 |
| June 30, 2017 | 0.1595 |
| March 31, 2017 | -17.77 |
| June 30, 2016 | |
| March 31, 2016 | 0.5609 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 205.74M |
| Total Liabilities (Quarterly) | 21.95M |
| Shareholders Equity (Quarterly) | 183.79M |
| Current Ratio | 10.01 |